Impaired vascular function, manifested by an altered ability of the endothelium to release
endothelium-derived relaxing factors and endothelium-derived contracting factors, is …

The endocannabinoid anandamide (AEA) causes vasorelaxation in animal studies.
Although circulating AEA levels are increased in many pathologies, little is known about its …

Recent studies suggest that endocannabinoid signaling is modulated by 17β-estradiol
(17Eβ) however it is unclear if this applies to the cardiovascular actions of anandamide, a …

Background and aims: Anandamide is an endocannabinoid that evokes hypotension by
interaction with peripheral cannabinoid CB1 receptors and with the perivascular transient …

Circulating levels of anandamide are increased in diabetes, and cannabidiol ameliorates a
number of pathologies associated with diabetes. The aim of the present study was to …

The hypotensive actions of methanandamide are enhanced in anaesthetised spontaneously
hypertensive rats (SHR), which may be due to increased sensory nerve activity. We have …

Background and purpose: Endocannabinoids in tissues controlling energy homeostasis are
altered in obesity, thus contributing to metabolic disorders. Here we evaluate …

Fatty acid amides are a new class of signaling lipids that have been implicated in diverse
physiological and pathological conditions. Oleamide is a fatty acid amide that induces …

The endogenous cannabinoid anandamide has recently been identified as a vasorelaxant
but the underlying mechanisms are controversial. The vasorelaxant responses to …

Aims This study examined whether the fall in blood pressure (BP) induced by the chronic
inhibition of fatty acid amide hydrolase (FAAH) by URB597 in deoxycorticosterone acetate …